In conclusion, treatment with GLP-1 RAs in adults with T2DM or obesity does not increase the risk of esophageal cancer, and there are probably no significant differences in risk across different GLP-1 RA types. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.